ASH 2022 | Targeting the interaction between Wnt5a and ROR1 in CLL

Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, describes the role of Wnt5a and highlights its potential as a drug target in chronic lymphocytic leukemia (CLL). Dr Kipps explains that Wnt5a is a key mediator of leukemic cell survival, and is found at higher levels in the plasma of patients with CLL compared to age-matched controls. In vitro studies have also confirmed that leukemic cells have improved survival in the presence of Wnt5a, with further in vitro experiments demonstrating that this Wnt5a-mediated survival advantage is dependent on the interaction between the Wnt5a and ROR1 proteins. This evidence suggests that the interaction between Wnt5a and ROR1 could be inhibited as a low-toxicity method of inhibiting leukemic cell growth. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.